|
1
|
Tixier F, Ranchon F, Iltis A, Vantard N, Schwiertz V, Bachy E, Bouafia-Sauvy F, Sarkozy C, Tournamille JF, Gyan E, Salles G, Rioufol C. Comparative toxicities of 3 platinum-containing chemotherapy regimens in relapsed/refractory lymphoma patients. Hematol Oncol 2016; 35:584-590. [DOI: 10.1002/hon.2328] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2016] [Accepted: 06/07/2016] [Indexed: 12/21/2022]
Affiliation(s)
- F. Tixier
- Unité de Pharmacie Clinique Oncologique; Hospices Civils de Lyon, Groupement Hospitalier Sud; Pierre-Bénite France
| | - F. Ranchon
- Unité de Pharmacie Clinique Oncologique; Hospices Civils de Lyon, Groupement Hospitalier Sud; Pierre-Bénite France
- EMR 3738; Université Lyon 1; Lyon France
| | - A. Iltis
- Service d'hématologie et thérapie cellulaire; Centre Hospitalier Universitaire de Tours; Tours France
| | - N. Vantard
- Unité de Pharmacie Clinique Oncologique; Hospices Civils de Lyon, Groupement Hospitalier Sud; Pierre-Bénite France
| | - V. Schwiertz
- Unité de Pharmacie Clinique Oncologique; Hospices Civils de Lyon, Groupement Hospitalier Sud; Pierre-Bénite France
| | - E. Bachy
- Service d'hématologie; Hospices Civils de Lyon, Groupement Hospitalier Sud; Lyon France
| | - F. Bouafia-Sauvy
- Service d'hématologie; Hospices Civils de Lyon, Groupement Hospitalier Sud; Lyon France
| | - C. Sarkozy
- Service d'hématologie; Hospices Civils de Lyon, Groupement Hospitalier Sud; Lyon France
| | - J. F. Tournamille
- Unité de Biopharmacie Clinique Oncologique; Centre Hospitalier Universitaire de Tours; Tours France
| | - E. Gyan
- Service d'hématologie et thérapie cellulaire; Centre Hospitalier Universitaire de Tours; Tours France
| | - G. Salles
- Service d'hématologie, Université Lyon 1, UMR5239; Hospices Civils de Lyon, Groupement Hospitalier Sud; Lyon France
| | - C. Rioufol
- Unité de Pharmacie Clinique Oncologique; Hospices Civils de Lyon, Groupement Hospitalier Sud; Pierre-Bénite France
- EMR 3738; Université Lyon 1; Lyon France
| |
Collapse
|
|
2
|
Castellino SM, Ullrich NJ, Whelen MJ, Lange BJ. Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors. J Natl Cancer Inst 2014; 106:dju186. [PMID: 25080574 DOI: 10.1093/jnci/dju186] [Citation(s) in RCA: 92] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Survivors of childhood cancer frequently experience cancer-related cognitive dysfunction, commonly months to years after treatment for pediatric brain tumors, acute lymphoblastic leukemia (ALL), or tumors involving the head and neck. Risk factors for cancer-related cognitive dysfunction include young age at diagnosis, treatment with cranial irradiation, use of parenteral or intrathecal methotrexate, female sex, and pre-existing comorbidities. Limiting use and reducing doses and volume of cranial irradiation while intensifying chemotherapy have improved survival and reduced the severity of cognitive dysfunction, especially in leukemia. Nonetheless, problems in core functional domains of attention, processing speed, working memory and visual-motor integration continue to compromise quality of life and performance. We review the epidemiology, pathophysiology and assessment of cancer-related cognitive dysfunction, the impact of treatment changes for prevention, and the broad strategies for educational and pharmacological interventions to remediate established cognitive dysfunction following childhood cancer. The increased years of life saved after childhood cancer warrants continued study toward the prevention and remediation of cancer-related cognitive dysfunction, using uniform assessments anchored in functional outcomes.
Collapse
Affiliation(s)
- Sharon M Castellino
- Department of Pediatrics, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC (SMC); Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC (SMC, MJW); Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA (NJU); Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, Philadelphia, PA (BJL).
| | - Nicole J Ullrich
- Department of Pediatrics, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC (SMC); Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC (SMC, MJW); Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA (NJU); Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, Philadelphia, PA (BJL)
| | - Megan J Whelen
- Department of Pediatrics, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC (SMC); Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC (SMC, MJW); Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA (NJU); Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, Philadelphia, PA (BJL)
| | - Beverly J Lange
- Department of Pediatrics, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC (SMC); Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC (SMC, MJW); Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA (NJU); Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, Philadelphia, PA (BJL)
| |
Collapse
|
|
3
|
Zauli G, Rimondi E, Celeghini C, Milani D, Secchiero P. Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL). J Cell Physiol 2010; 222:357-64. [DOI: 10.1002/jcp.21960] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|